Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective

被引：0
|
作者：
Barbara Fischer
Andreas Serra
Harry Telser
机构：
[1] Polynomics,Department of Internal Medicine and Nephrology
[2] Klinik Hirslanden,Center for Health, Policy and Economics
[3] University of Lucerne,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
Chronic kidney disease; Hyperkalemia; Patiromer; Potassium binder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2717 / 2730
页数：13
相关论文
共 37 条
  • [31] Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial
    Garcia-Prieto, A. M.
    Verdalles, U.
    de Jose, A. P.
    Arroyo, D.
    Aragoncillo, I.
    Barbieri, D.
    Camacho, R. E.
    Goicoechea, M.
    HIPERTENSION Y RIESGO VASCULAR, 2024, 41 (02): : 95 - 103
  • [32] Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer Perspective
    Igarashi, Ataru
    Ohara, Kenichi
    Matsuda, Hiroyuki
    Morii, Junko
    Jagannathan, Suchitra
    Filomeno, Ronald
    ADVANCES IN THERAPY, 2025, 42 (02) : 995 - 1008
  • [33] A systematic review and meta-analysis of the clinical impact of stopping renin-angiotensin system inhibitor in patients with chronic kidney disease
    Nakayama, Takashin
    Mitsuno, Ryunosuke
    Azegami, Tatsuhiko
    Sato, Yasunori
    Hayashi, Kaori
    Itoh, Hiroshi
    HYPERTENSION RESEARCH, 2023, 46 (06) : 1525 - 1535
  • [34] The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design
    Garcia-Prieto, A. M.
    Verdalles, U.
    de Jose, A. P.
    Verde, E.
    Arroyo, D.
    Aragoncillo, I
    Linares, T.
    Barbieri, D.
    Goicoechea, M.
    HIPERTENSION Y RIESGO VASCULAR, 2020, 37 (03): : 101 - 107
  • [35] Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study
    Onuigbo, Macaulay A. C.
    Onuigbo, Nnonyelum T. C.
    RENAL FAILURE, 2008, 30 (01) : 67 - 72
  • [36] Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients
    Kwakernaak, Arjan J.
    Waanders, Femke
    Slagman, Maartje C. J.
    Dokter, Martin M.
    Laverman, Gozewijn D.
    de Boer, Rudolf A.
    Navis, Gerjan
    JOURNAL OF HYPERTENSION, 2013, 31 (12) : 2425 - 2432
  • [37] Comparison of the Antialbuminuric Effects of Benidipine and Hydrochlorothiazide in Renin-Angiotensin System (RAS) Inhibitor-Treated Hypertensive Patients with Albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics TreatMent with RAS inhibitOrs in a Chronic Kidney Disease Hypertensive Population) Study
    Ando, Katsuyuki
    Nitta, Kosaku
    Rakugi, Hiromi
    Nishizawa, Yoshiki
    Yokoyama, Hitoshi
    Nakanishi, Takeshi
    Kashihara, Naoki
    Tomita, Kimio
    Nangaku, Masaomi
    Takahashi, Katsutoshi
    Isshiki, Masashi
    Shimosawa, Tatsuo
    Fujita, Toshiro
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2014, 11 (09): : 897 - 904
1234